NDC product
Guaifenesin and Pseudoephedrine HCL
NDC 55111-799 · Dr. Reddys Laboratories Limited
Key facts
| Product NDC | 55111-799 |
|---|---|
| Proprietary name | Guaifenesin and Pseudoephedrine HCL |
| Nonproprietary name | Guaifenesin and Pseudoephedrine HCL |
| Substances | GUAIFENESIN, PSEUDOEPHEDRINE HYDROCHLORIDE |
| Dosage form | TABLET, EXTENDED RELEASE |
| Route | ORAL |
| Labeler | Dr. Reddys Laboratories Limited |
| Product type | HUMAN OTC DRUG |
| Marketing category | ANDA |
| Application number | ANDA208369 |
| Pharmacologic classes | Adrenergic alpha-Agonists [MoA], Decreased Respiratory Secretion Viscosity [PE], Expectorant [EPC], Increased Respiratory Secretions [PE], alpha-Adrenergic Agonist [EPC] |
| Marketing start | Dec 29, 2017 |
| Listing certified through | Dec 31, 2027 |
At a glance
- 1–9 Package NDCs
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About National Drug Codes (NDC)
The National Drug Code (NDC) is the FDA's product identifier for drugs; the product NDC identifies the labeler and product, and each package adds a package code.
Source: U.S. Food and Drug Administration (FDA), National Drug Code Directory · Source date: